Related content

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

By Castellano Daniel  

Cancer and Metastasis Reviews, Vol. 30, Iss. 1, 2011-03 ,pp. : 1-1

Springer Publishing Company

Access to resources Recommend Favorite

Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center

By Yildiz Ozcan  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1050-1056

Humana Press, Inc

Access to resources Recommend Favorite

Compound gastroenteropancreatic neuroendocrine and gastrointestinal stromal tumors in the stomach: A case report

By      

Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. : 2996-2998

Spandidos Publications

Access to resources Recommend Favorite

Prognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas

By Ranuncolo Stella   Varela Mirta   Morandi Ana   Lastiri José   Christiansen Silvia   Bal de Kier Joffé Elisa   Pallotta María   Puricelli Lydia  

Journal of Neuro-Oncology, Vol. 68, Iss. 2, 2004-06 ,pp. : 113-121

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic Significance of p53 Expression in Ovarian Granulosa Cell Tumors

By Ala-Fossi S.-L.   Maenpaa J.   Aine R.   Koivisto P.   Koivisto A.-M.   Punnonen R.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 475-479

Elsevier

Access to resources Recommend Favorite